These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15689157)

  • 1. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
    Lu H; Chang DJ; Baratte B; Meijer L; Schulze-Gahmen U
    J Med Chem; 2005 Feb; 48(3):737-43. PubMed ID: 15689157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
    Khuntawee W; Rungrotmongkol T; Hannongbua S
    J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for CDK6 activation by a virus-encoded cyclin.
    Schulze-Gahmen U; Kim SH
    Nat Struct Biol; 2002 Mar; 9(3):177-81. PubMed ID: 11828325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition.
    Lu H; Schulze-Gahmen U
    J Med Chem; 2006 Jun; 49(13):3826-31. PubMed ID: 16789739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
    Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
    Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
    Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
    J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
    Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
    Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.
    Brotherton DH; Dhanaraj V; Wick S; Brizuela L; Domaille PJ; Volyanik E; Xu X; Parisini E; Smith BO; Archer SJ; Serrano M; Brenner SL; Blundell TL; Laue ED
    Nature; 1998 Sep; 395(6699):244-50. PubMed ID: 9751051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells.
    Van Dross R; Yao S; Asad S; Westlake G; Mays DJ; Barquero L; Duell S; Pietenpol JA; Browning PJ
    J Natl Cancer Inst; 2005 May; 97(9):656-66. PubMed ID: 15870436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
    De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of CDK5/p25 binding by CDK inhibitors.
    Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
    J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
    Villacañas O; Pérez JJ; Rubio-Martínez J
    J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.
    Chou KC; Watenpaugh KD; Heinrikson RL
    Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
    Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
    Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.